CIBD
MCID: CYT004
MIFTS: 31

Cytomegalic Inclusion Disease (CIBD)

Categories: Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Cytomegalic Inclusion Disease

MalaCards integrated aliases for Cytomegalic Inclusion Disease:

Name: Cytomegalic Inclusion Disease 52
Cytomegalic Inclusion Body Disease 52 53 71
Giant Cell Inclusion Disease 52 53
Cytomegalovirus Infections 71
Cibd 52

Classifications:



External Ids:

UMLS 71 C0010823 C2931866

Summaries for Cytomegalic Inclusion Disease

NINDS : 53 Cytomegalovirus (CMV) is a virus found throughout the world that infects between 50 to 80 percent of all adults in the United States by the age of 40.  CMV is in the same family of viruses that causes cold sores (herpes simplex virus), infectious mononucleosis (Epstein-Barr virus), and chickenpox/shingles (varicella zoster virus).    Most people who acquire CVM as children or adults display no signs of illness or have mild symptoms such as fever, fatigue, or tender lymph nodes.  People with a compromised immune system may have more severe forms of infection involving the nervous system. A hallmark of CMV infection is that the virus cycles through periods of dormancy and active infection during the life of the individual  Infected persons of any age periodically shed the virus in their body fluids, such as saliva, urine, blood, tears, semen, or breast milk.  CMV is most commonly transmitted when infected body fluids come in contact with the mucous membranes of an uninfected person, but the virus can also pass from mother to fetus during pregnancy.

MalaCards based summary : Cytomegalic Inclusion Disease, also known as cytomegalic inclusion body disease, is related to cytomegalovirus infection and toxoplasmosis, and has symptoms including fever and pruritus. The drugs Triamcinolone and Valganciclovir have been mentioned in the context of this disorder. Affiliated tissues include t cells, kidney and testes.

Wikipedia : 74 Cytomegalovirus (CMV) (from the Greek cyto-, "cell," and megalo-, "large") is a genus of viruses in the... more...

Related Diseases for Cytomegalic Inclusion Disease

Diseases related to Cytomegalic Inclusion Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 104)
# Related Disease Score Top Affiliating Genes
1 cytomegalovirus infection 10.6
2 toxoplasmosis 10.4
3 rubella 10.4
4 leukemia 10.3
5 herpes simplex 10.3
6 encephalitis 10.3
7 rhinitis 10.2
8 liver cirrhosis 10.2
9 inflammatory bowel disease 10.2
10 urolithiasis 10.2
11 tic disorder 10.2
12 pfeiffer syndrome 10.2
13 anemia, autoimmune hemolytic 10.2
14 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 10.2
15 wiskott-aldrich syndrome 10.2
16 aspergillosis 10.2
17 deficiency anemia 10.2
18 mumps 10.2
19 osteomalacia 10.2
20 pneumocystosis 10.2
21 nephrotic syndrome 10.2
22 thrombocytopenia 10.2
23 neonatal jaundice 10.2
24 purpura 10.2
25 hemolytic anemia 10.2
26 acquired immunodeficiency syndrome 10.2
27 childhood leukemia 10.2
28 myocarditis 10.2
29 measles 10.2
30 vasculitis 10.2
31 chickenpox 10.2
32 chorioretinitis 10.2
33 macroglobulinemia 10.2
34 congenital cytomegalovirus 10.2
35 congenital rubella 10.2
36 otitis media 10.1
37 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.1
38 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.1
39 omphalocele 10.1
40 bacterial infectious disease 10.1
41 gastric ulcer 10.1
42 hodgkin's paragranuloma 10.1
43 tuberculous meningitis 10.1
44 atrial standstill 1 10.0
45 fibrosis of extraocular muscles, congenital, 1 10.0
46 congenital heart defects, hamartomas of tongue, and polysyndactyly 10.0
47 endocardial fibroelastosis 10.0
48 lymphoma, hodgkin, classic 10.0
49 immune deficiency disease 10.0
50 sudden infant death syndrome 10.0

Graphical network of the top 20 diseases related to Cytomegalic Inclusion Disease:



Diseases related to Cytomegalic Inclusion Disease

Symptoms & Phenotypes for Cytomegalic Inclusion Disease

UMLS symptoms related to Cytomegalic Inclusion Disease:


fever, pruritus

Drugs & Therapeutics for Cytomegalic Inclusion Disease

Drugs for Cytomegalic Inclusion Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 180)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
2
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
3
Ganciclovir Approved, Investigational Phase 4 82410-32-0 3454
4
Foscarnet Approved Phase 4 4428-95-9, 63585-09-1 3415
5
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
6
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
7
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
8
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
9
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
10
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
11
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
12
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
13
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
14 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
15
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
16
tannic acid Approved Phase 4 1401-55-4
17
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
18
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
19
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
20
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
21
Mycophenolic acid Approved Phase 4 24280-93-1 446541
22
Azathioprine Approved Phase 4 446-86-6 2265
23
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
24
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
25
Darunavir Approved Phase 4 206361-99-1, 635728-49-3 213039
26
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
27
Dolutegravir Approved Phase 4 1051375-16-6 54726191
28
Phosphonoacetic Acid Experimental Phase 4 4408-78-0 546
29
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
30
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
31 Triamcinolone diacetate Phase 4
32 triamcinolone acetonide Phase 4
33 Triamcinolone hexacetonide Phase 4
34 Antiviral Agents Phase 4
35 Anti-Infective Agents Phase 4
36 Ganciclovir triphosphate Phase 4
37 Anti-Retroviral Agents Phase 4
38 Liver Extracts Phase 4
39 Reverse Transcriptase Inhibitors Phase 4
40 Hormones Phase 4
41 Anti-Arrhythmia Agents Phase 4
42 Tocolytic Agents Phase 4
43 Anticonvulsants Phase 4
44 Calcium, Dietary Phase 4
45 Anesthetics Phase 4
46 calcium channel blockers Phase 4
47 Immunosuppressive Agents Phase 4
48 Immunologic Factors Phase 4
49 Gastrointestinal Agents Phase 4
50 Cyclosporins Phase 4

Interventional clinical trials:

(show top 50) (show all 288)
# Name Status NCT ID Phase Drugs
1 An Exploratory Evaluation of Early Use of Everolimus (EVE) on Tacrolimus (TAC)-Based Immunosuppressive Regiment vs. Mycophenolate Sodium (MPS) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients. Unknown status NCT01927588 Phase 4 Everolimus+Tacrolimus+Prednisone;Mycophenolate+Tacrolimus+Prednisone
2 Tolerability of up to 200 Days of Valganciclovir Oral Solution or Tablets in Pediatric Kidney Transplant Recipients Completed NCT01376804 Phase 4 valganciclovir [Valcyte]
3 A Multicenter Prospective Cohort Study to Investigate if Ganciclovir Significantly Affects Spermatogenesis in Adult Male Renal Transplant Recipients Receiving up to 200 Days Valganciclovir Vs. Concurrent Untreated Matched Controls Completed NCT01663740 Phase 4 Valganciclovir
4 A Randomized, Open-label Study of the Effect of Oral Valcyte Versus Intravenous Ganciclovir on CMV Viremia in Solid Organ Transplant Patients Completed NCT00431353 Phase 4 Ganciclovir;valganciclovir [Valcyte]
5 Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study Completed NCT00002146 Phase 4 Magnesium sulfate;Foscarnet sodium
6 Valganciclovir to Reduce T Cell Activation in HIV Infection Completed NCT00264290 Phase 4 Valganciclovir;Placebo
7 The Influence of Chronic Cytomegalovirus Infection on Influenza Vaccine Responses Completed NCT02134184 Phase 4
8 A Multicenter Study of Oral Versus Intravenous Hydration in AIDS Patients With CMV Retinitis Treated With Foscavir (Foscarnet Sodium) Completed NCT00002125 Phase 4 Foscarnet sodium
9 Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for CMV Infection Completed NCT01509404 Phase 4 Valganciclovir;Valganciclovir
10 Influence of Persistent CMV-infection on Immune Senescence Evaluated With a Prospective Vaccination Trial Against Tick-borne Encephalitis Virus in Healthy Elderly Individuals (CYTEL-Study) Completed NCT00461695 Phase 4
11 Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in High-Risk R-D+ Liver Transplant Recipients Completed NCT01552369 Phase 4 Valganciclovir
12 Phase IV.II Pilot Study of Treatment of Cytomegalovirus Infection With a Brief Induction With Ganciclovir i.v. Followed by Valganciclovir Oral in Solid Organ Transplant Patients. Completed NCT00730769 Phase 4 Single arm (ganciclovir and valganciclovir)
13 Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients: A Prospective Randomized Controlled Trial Completed NCT02683291 Phase 4 sirolimus;tacrolimus;mycophenolate;Prednisone;Basiliximab;Thymoglobulin
14 Open, Randomised Study Comparing Preemptive Therapy With Intravenous Ganciclovir With and Without Additional Oral Ganciclovir for CMV Prophylaxis in Immunosuppressed Renal Transplant Patients Receiving Monitoring of CMV Viral Load Completed NCT00373165 Phase 4 Ganciclovir
15 Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate Completed NCT01354301 Phase 4 Thymoglobulin;Everolimus;Basiliximabe;mycophenolate sodium;Tacrolimus;Tacrolimus;Tacrolimus
16 Determining a Viral Load Threshold for Pre-emptive Therapy for Cytomegalovirus Infection in Transplant Patients Using Real Time Polymerase Chain Reaction (PCR) Monitoring Completed NCT00947141 Phase 4 ganciclovir (start when CMV PCR >200copies / ml x2);Stop treatment when 2 levels CMV PCR <3,000 copies / ml
17 Everolimus in Association With Very Low-dose Tacrolimus Versus Enteric-coated Mycophenolate Sodium With Low-dose Tacrolimus in de Novo Renal Transplant Recipients - A Prospective Single Center Study Completed NCT02084446 Phase 4 Everolimus;Very Low Tacrolimus;Low Tacrolimus;Steroids;Thymoglobulin;Sodium Mycophenolate
18 A Multicenter, Two Arms, Randomized, Open Label Clinical Phase IV Study Investigating the Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection Within the First 6 Months Post-transplantation When Treated With an Immunosuppressive Regimen Including Everolimus (Certican®) and Reduced Dose of Cyclosporine A (Neoral®) Versus an Immunosuppressive Regimen With Mycophenolic Acid (Myfortic®) and Standard Dose of Cyclosporine A (Neoral®). Completed NCT02328963 Phase 4 Everolimus;mycophenolic acid
19 A Prospective Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection According to Baseline hCMV-specific T-cell Response in Kidney Transplant Patients (RESPECT) Completed NCT02550639 Phase 4
20 Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence in Kidney Transplant Recipients (StopCMV: S=Sirolimus CMV= Cytomegalovirus) Recruiting NCT02671318 Phase 4 Drug conversion to sirolimus;Maintenance of the current regimen
21 Intra-cameral Penetration and Efficacy of Ganciclovir Following Topical Administration of 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis Recruiting NCT02943057 Phase 4 2% guttae ganciclovir
22 Cytomegalovirus Specific Cytotoxic T Lymphocyte for the Treatment of Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation Recruiting NCT03004261 Phase 4 Foscarnet;Ganciclovir
23 Phase IV Clinical Trial, Open, Randomized, Controlled and Multicentric, With Two Parallel Groups, to Assess the Efficacy of a Preventive Strategy Against Cytomegalovirus Infection in Heart Transplant Patients, Based on the Specific Basal T Cell Response Against Cytomegalovirus: ELISPOT-TC Not yet recruiting NCT04278547 Phase 4
24 The Impact of Co-infections on Inflammation in Patients Commencing Second-line Antiretroviral Therapy. A Sub-study of D²EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy) Not yet recruiting NCT04183738 Phase 4 NRTIs;Darunavir;Ritonavir;Dolutegravir
25 Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy Terminated NCT00264368 Phase 4 intravenous (IV) ganciclovir
26 In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir: Prospective Multicenter Randomized Trial Versus Placebo Terminated NCT01037712 Phase 4 Valacyclovir (ZELITREX);Placebo
27 The Leiden CONCERT Study 2.0 Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Non-Randomized Trial With Historical Control Group Unknown status NCT02005822 Phase 3 Valganciclovir
28 Efficacy and Safety of Anti-cytomegalovirus Prophylaxis Versus Pre-emptive Approaches With Valganciclovir in Heart Transplant Recipients Treated With Everolimus or Mycophenolate. A Randomized Open-label Study for Prevention of Cardiaca Allograft Vasculopathy Unknown status NCT00966836 Phase 3 Pre-emptive strategy with valganciclovir plus everolimus;Prophylaxis with valganciclovir plus mycophenolate;Prophylaxis with valganciclovir plus everolimus;Pre-emptive mycophenolate
29 Safety and Pharmacokinetics of Valganciclovir Syrup Formulation in Pediatric Solid Organ Transplant Recipients Completed NCT00090766 Phase 2, Phase 3 valganciclovir [Valcyte]
30 Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection Completed NCT00004278 Phase 3 ganciclovir
31 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients Completed NCT00294515 Phase 3 Valganciclovir;Valganciclovir
32 A Randomized, Double-Blind Trial of Valacyclovir Hydrochloride (BW 256U87) Prophylaxis for Opportunistic Cytomegalovirus End-Organ Disease in Patients With Advanced HIV Infection (< 100 CD4+ Lymphocytes) Completed NCT00001038 Phase 3 Valacyclovir hydrochloride;Acyclovir
33 Participation of Cytomegalovirus Infection or an Autoimmune Process in T Lymphocyte Activation of HIV-1 Infected Patients With Undetectable Viral Load on Antiretroviral Therapy. Completed NCT04067869 Phase 3
34 A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants. Completed NCT00411645 Phase 3 maribavir
35 Transfusion-Transmitted Cytomegalovirus Prevention in Neonates Completed NCT00000584 Phase 3 immunoglobulins
36 A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections. Completed NCT00001100 Phase 3 ganciclovir
37 A Phase III, Randomized, Double-Blind Comparison of Oral Valganciclovir and Placebo for Prevention of CMV After Lung Transplantation Completed NCT00227370 Phase 3 valganciclovir
38 A Randomized, Double-blind Study To Assess The Efficacy And Safety Of Prophylactic Use Of Maribavir Versus Oral Ganciclovir For The Prevention Of Cytomegalovirus Disease In Recipients Of Orthotopic Liver Transplants Completed NCT00497796 Phase 3 maribavir;ganciclovir
39 A Phase III, Prospective, Randomized, Double-Blind Trial of Valganciclovir Pre-Emptive Therapy for Cytomegalovirus (CMV) Viremia as Detected by Plasma CMV DNA PCR Assay Completed NCT00006145 Phase 3 Valganciclovir
40 Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy Completed NCT02351102 Phase 2, Phase 3 Valacyclovir;Placebo
41 Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease Completed NCT00002145 Phase 3 Foscarnet sodium
42 Phase III Ganciclovir +/- rGM-CSF for AIDS-Related CMV Retinitis Completed NCT00002070 Phase 3 Sargramostim;Ganciclovir
43 A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients Completed NCT02137772 Phase 3 Letermovir;Placebo
44 A Randomized Trial Comparing Valcyte CMV Prophylaxis Versus Pre-emptive Therapy After Renal Transplantation Using Proteomics for Monitoring of Graft Alteration Completed NCT00372229 Phase 3 Valganciclovir CMV Prophylaxis;Valganciclovir (Pre-emptive CMV Therapy);Ganciclovir
45 A Randomized, Controlled Study of Intravenous Ganciclovir Therapy for Peripheral Cytomegalovirus Retinitis in Patients With AIDS Completed NCT00000688 Phase 3 Ganciclovir
46 Phase III Study Evaluating the Safety and Efficacy of Artesunate in Preemptive Treatment of Human Cytomegalovirus Disease in Stem Cell Transplant Recipients Completed NCT00284687 Phase 3 Artesunate
47 Prevention of Human Cytomegalovirus (HCMV) Mother-to-fetus Transmission by Administration of Virus-specific Hyperimmune Globulin to Pregnant Women With Primary HCMV Infection Completed NCT00881517 Phase 2, Phase 3 HCMV-specific hyperimmune globulin (Cytotect®);Isotonic solution of sodium chloride (placebo)
48 A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Adefovir Dipivoxil (Bis-POM PMEA) in Prolonging Survival of HIV-Infected Individuals With a CD4+ Cell Count of <= 100/mm3 or With a CD4+ Cell Count Both > 100 and <= 200/mm3 and a Nadir CD4+ Cell Count of <= 50/mm3 Completed NCT00001082 Phase 3 Levocarnitine;Adefovir dipivoxil;Adefovir dipivoxil placebo
49 A Treatment Protocol for the Use of Intravenous Ganciclovir in AIDS Patients With Immediately Sight-Threatening CMV Retinitis Completed NCT00000698 Phase 3 Ganciclovir
50 A Phase III Multicenter Study Of Valganciclovir For The Prevention Of Late Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT00016068 Phase 3 ganciclovir;valganciclovir

Search NIH Clinical Center for Cytomegalic Inclusion Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cidofovir
Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]
Cytomegalovirus Pyrophosphate Analog DNA Polymerase Inhibitor [EPC]
Foscarnet
Foscarnet Sodium Hexahydrate
Ganciclovir
Ganciclovir Sodium
Immunoglobulins, Intravenous
valganciclovir
Valganciclovir hydrochloride

Genetic Tests for Cytomegalic Inclusion Disease

Anatomical Context for Cytomegalic Inclusion Disease

MalaCards organs/tissues related to Cytomegalic Inclusion Disease:

40
T Cells, Kidney, Testes, Breast, Liver, Bone, Brain

Publications for Cytomegalic Inclusion Disease

Articles related to Cytomegalic Inclusion Disease:

(show top 50) (show all 467)
# Title Authors PMID Year
1
Congenital cytomegalic inclusion disease with disseminated Herpes simplex infection. 61
31025643 2019
2
Isolated renal involvement of cytomegalovirus inclusion disease in an infant. 61
29456230 2018
3
Cytomegalic Inclusion Disease caused by Cytomegalovirus Infection in the Salivary Glands of an African Hedgehog (Atelerix arbiventris). 61
29169627 2017
4
Bilateral congenital cataract with suspected lens-induced granulomatous uveitis. 61
25262559 2014
5
Psychomotor development after ganciclovir selectively treated congenital and perinatal cytomegalovirus infection. 61
23441468 2012
6
Problems and challenges in the diagnosis of vertical infection with human cytomegalovirus (CMV): lessons from two accidental cases. 61
21641276 2011
7
Cytomegalovirus glycoprotein B gene polymorphism and its association with clinical presentations in infants. 61
19842410 2009
8
Pregnancy and sexually transmitted viral infections. 61
21938124 2009
9
The prognostic value of ultrasound abnormalities and biological parameters in blood of fetuses infected with cytomegalovirus. 61
18485159 2008
10
Human cytomegalovirus glycoprotein B genotype correlates with different symptoms of infected infants. 61
17356299 2007
11
[Effects of HCMV on phenotypes of parotid duct epithelial cells and its mechanisms]. 61
16027778 2005
12
Stalemating a clever opportunist: lessons from murine cytomegalovirus. 61
15172444 2004
13
Determination of human cytomegalovirus genetic diversity in different patient populations in Costa Rica. 61
15141278 2004
14
Brain slice culture for analysis of developmental brain disorders with special reference to congenital cytomegalovirus infection. 61
12893969 2003
15
Delivery room risk factors for meconium aspiration syndrome. 61
12442226 2002
16
Prenatal diagnosis of congenital cytomegalovirus infection in 189 pregnancies with known outcome. 61
11360277 2001
17
Severe fetal cytomegalic inclusion disease after documented maternal reactivation of cytomegalovirus infection during pregnancy. 61
10740207 2000
18
Gastro-intestinal cytomegalovirus infection and extensive colonic ulceration in a renal transplant recipient. 61
11830710 1998
19
Cytomegalovirus enteritis in a premature infant. 61
9396521 1997
20
Cytomegalovirus infection in the pregnant mother, fetus, and newborn infant. 61
9099507 1997
21
[Albert Jesionek tracking cytomegalovirus disease]. 61
9264964 1997
22
[Immunohistochemical detection of antigen of human cytomegalovirus in hepatocyte]. 61
9208619 1996
23
A fatal case of congenital cytomegalic inclusion disease following recurrent maternal infection. 61
8590396 1995
24
TORCH syndrome. 61
7640200 1995
25
Disseminated cutaneous cytomegalic inclusion disease resembling prurigo nodularis in a HIV-infected patient: a case report and literature review. 61
7964230 1993
26
[Treatment of cytomegalic inclusion disease with acyclovir and hyper-immune immunoglobulins in newborn infants]. 61
8002755 1993
27
Temporal bone histopathology 14 years after cytomegalic inclusion disease: a case study. 61
8395628 1993
28
Improvement of serological diagnosis of human cytomegalovirus infection in renal transplant recipients by testing for specific immunoglobulin E by ELISA. 61
8396070 1993
29
Humoral immune response to human cytomegalovirus infection: diagnostic potential of immunoglobulin class and IgG subclass antibody response to human cytomegalovirus early and late antigens. 61
8386033 1993
30
[Cytomegalovirus]. 61
8384864 1993
31
Cytomegalic inclusion disease presenting acute intrahepatic cholestasis. 61
1338619 1992
32
Comparison of shell viral culture and serology for the diagnosis of human cytomegalovirus infection in neonates and immunocompromised subjects. 61
1327325 1992
33
Laboratory diagnosis of congenital human cytomegalovirus infection using polymerase chain reaction and shell vial culture. 61
1322865 1992
34
[Generalized congenital cytomegalic inclusion disease. A case report of a fulminant course of cytomegalic infection]. 61
1320269 1992
35
[Congenital cytomegalic inclusion disease--clinico-anatomical characteristics]. 61
1336321 1992
36
Cytomegalovirus fetal infection: prenatal diagnosis. 61
1656349 1991
37
Salivary gland oncocytes in African hedgehogs (Atelerix albiventris) mimicking cytomegalic inclusion disease. 61
1655834 1991
38
[An autopsy case of cardiomyopathy combined with nephrotic syndrome and pulmonary cytomegalic inclusion disease]. 61
1648780 1991
39
Successful treatment of disseminated cutaneous cytomegalic inclusion disease associated with Hodgkin's disease. 61
1847957 1991
40
[A case from practice (208). Cytomegalic inclusion disease]. 61
1849666 1991
41
Cytomegalic inclusion disease: intrauterine sonographic diagnosis using findings involving the brain. 61
1846993 1991
42
Antibodies against human CMV-induced "early" antigens detected by immunoblotting are not exclusively associated with active infection. 61
1647051 1991
43
[Cytomegalic inclusion disease in a patient with systemic lupus]. 61
1648251 1991
44
[An autopsy case of cytomegalic inclusion disease with severe enteritis and jaundice]. 61
2166843 1990
45
[Clinico-morphological characteristics of the family of diseases: cytomegalic inclusion disease, iatrogenic thesaurismosis and septicemia]. 61
1696711 1990
46
A viral infection causing cytomegalic inclusion disease in the renal epithelium of the platypus (Ornithorhynchus anatinus). 61
2154629 1990
47
[Gastric ulcer as a unique and symptomatic manifestation of infection by cytomegalovirus in a healthy adult]. 61
2560102 1989
48
[A 9-week-old infant with congenital cytomegalic inclusion disease and therapy with ganciclovir]. 61
2552691 1989
49
[Prevention of cytomegalic inclusion disease in leukemia patients with a cytomegalovirus hyperimmune globulin preparation]. 61
2550700 1989
50
Cytomegalovirus (CMV) disease of the brain in AIDS and connatal infection: a comparative study by histology, immunocytochemistry and in situ DNA hybridization. 61
2558487 1989

Variations for Cytomegalic Inclusion Disease

Expression for Cytomegalic Inclusion Disease

Search GEO for disease gene expression data for Cytomegalic Inclusion Disease.

Pathways for Cytomegalic Inclusion Disease

GO Terms for Cytomegalic Inclusion Disease

Sources for Cytomegalic Inclusion Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....